Clinical trials: Prostate Disease
Prostate Cancer
Intermittent Treatment With Degarelix of Patients Suffering From Prostate Cancer
The purpose of this uncontrolled, multi-center, open-label trial was to investigate the feasibility of using degarelix as intermittent androgen deprivation (IAD) therapy in the treatment of prostate cancer.
- Trial name
- NCT00801242
- Testing
- Degarelix 240 mg / 80 mg
- Where
- 52 sites in Belgium, France and 4 more
- Volunteers
- 220 people
- Sponsor
- Ferring Pharmaceuticals
Prostate Cancer
Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC)
The SPERA trial is designed to 1. provide satraplatin to physicians with patients who have hormone refractory prostate cancer (HRPC) which has progressed following unlimited cytotoxic chemotherapy regimens for metastatic disease…
- Trial name
- SPERA (NCT00450970)
- Testing
- Oral Satraplatin
- Where
- 121 sites in United States
- Volunteers
- 344 people
- Sponsor
- Agennix
Prostate Cancer, Non Small Cell Lung Cancer
First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine
OVM-200 will be tested in humans for the first time in Study OVM-200-100. Up to 52 patients aged 18-75 with prostate, lung or ovarian cancer will be enrolled in the Study to find out if OVM-200 is safe to continue studying it in…
- Conditions
- Prostate Cancer, Non Small Cell Lung Cancer, Ovarian Cancer
- Trial name
- NCT05104515
- Testing
- OVM-200
- Where
- 4 sites in United Kingdom
- Volunteers
- 36 people
- Sponsor
- Oxford Vacmedix UK Ltd.
Bladder Cancer, Breast Cancer
A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors
Picoplatin is a new platinum-based chemotherapy drug that has been studied in a variety of cancers. Phase 1 and 2 studies have demonstrated that picoplatin may be effective in patients whose cancer returns or does not improve…
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastrointestinal Neoplasm
- Trial name
- NCT00465725
- Testing
- Picoplatin
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Poniard Pharmaceuticals
Prostate Cancer
Comparison of Trelstar Versus Lupron or Zoladex in Advanced Prostate Cancer
This research study looks at Testosterone levels in patients receiving Trelstar versus those receiving Lupron or Zoladex. These drugs have been approved for treatment of Prostate Cancer by the FDA.
- Trial name
- NCT02749825
- Testing
- Trelstar, Lupron, Zoladex
- Where
- 11 sites in United States
- Volunteers
- 41 people
- Sponsor
- Pharmatech
Prostate Cancer, Breast Cancer
A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED)
This study will determine the best doses of docetaxel and lonafarnib when the two anti-cancer agents are used in combination. Patients with tumors for which treatment with docetaxel would be appropriate are eligible.
- Conditions
- Prostate Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer
- Trial name
- NCT00539968
- Testing
- Docetaxel plus lonafarnib
- Volunteers
- 5 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Castration-resistant Prostate Cancer
Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.
This is a 2-part study in patients with metastatic CRPC. Part A is an open-label safety run-in study to assess the safety, tolerability and pharmacokinetics (PK) of olaparib when given in addition to abiraterone 1000 mg once…
- Trial name
- NCT01972217
- Testing
- Olaparib, Abiraterone, Prednisone or prednisolone
- Where
- 41 sites in United States, Belgium and 9 more
- Volunteers
- 158 people
- Sponsor
- AstraZeneca
Prostatic Neoplasms, Prostate Cancer
Multi-Center Trial of High-resolution Transrectal Ultrasound Versus Standard Low-resolution Transrectal Ultrasound for the Identification of Clinically Significant Prostate Cancer
This trial uses a ultra high-resolution ultrasound system and specialized transducer, intended for use in prostate imaging. The system's image resolution is significantly better than the standard of care, due to its higher…
- Conditions
- Prostatic Neoplasms, Prostate Cancer, Cancer of the Prostate
- Trial name
- NCT02079025
- Testing
- High-resolution ultrasound guided prostate biopsy, Standard ultrasound guided prostate biopsy
- Where
- 5 sites in United States, Canada
- Volunteers
- 1,676 people
- Sponsor
- Exact Imaging
Prostatic Cancer
Metabolic Changes in Prostate Cancer Patients With Androgen-ablation Therapy (AAT)
This is an observational, prospective, non-interventional and multi-centre study, to assess the impact of androgen ablation therapy in blood triglycerides, cholesterol and glucose, body fat distribution and fracture risk to ten…
- Trial name
- UROCOR (NCT01284608)
- Where
- 33 sites in Spain
- Volunteers
- 197 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Cancer, Advanced Solid Tumor
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in…
- Conditions
- Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma
- Trial name
- PRESERVE-001 (NCT04140526)
- Testing
- ONC-392, Pembrolizumab, Docetaxel
- Where
- 37 sites in United States, Australia
- Volunteers
- 733 people
- Sponsor
- OncoC4, Inc.
Prostate Cancer
Evaluation of the Sentinel™ PCC4 Assay for Diagnosis, Prognosis and Monitoring of Prostate Cancer in Puerto Rico
The miR Scientific Sentinel™ Prostate Cancer Classifier Platform (Sentinel™ PCC4 Assay) is a new molecular assay that interrogates 442 small non-coding RNAs extracted from urinary exosomes and provides urologists an early, very…
- Trial name
- NCT04661176
- Testing
- miR Sentinel™ PCC4 Assay
- Where
- 3 sites in Puerto Rico
- Volunteers
- 500 people
- Sponsor
- miR Scientific LLC
BPH With Symptomatic Lower Urinary Tract Symptoms
ProVee Urethral Expander System IDE Study (ProVIDE)
A study to evaluate the safety, performance, and effectiveness of the ProVee Urethral Expander System (Investigational Device) when used in subjects with symptomatic urinary obstruction related to benign prostatic hyperplasia…
- Trial name
- ProVIDE (NCT05186740)
- Testing
- ProVee Urethral Expander System, Urethral Access Sheath
- Where
- 16 sites in United States, Canada and 1 more
- Volunteers
- 221 people, healthy volunteers welcome
- Sponsor
- ProVerum Medical
Benign Prostate Hyperplasia, Healthy
Safety and Pharmacokinetic Characteristics of DKF-313
This is a randomized, open-label, single-dose, 2-treatment, 2-way, 2-period crossover study to evaluate the safety and the pharmacokinetic characteristics of DKF-313 (dutasteride and tadalafil) in healthy male volunteers.
- Trial name
- NCT02352311
- Testing
- DKF-313, AVODART, CIALIS
- Where
- South Korea
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Dongkook Pharmaceutical Co., Ltd.
Hormonal Refractory Prostate Cancer
Safety and Efficacy Trial of a RNActive®-Derived Prostate Cancer Vaccine in Hormone Refractory Disease
The purpose of this study is to determine the efficacy and safety of a new vaccine in hormone refractory prostate cancer
- Trial name
- NCT00831467
- Testing
- CV9103
- Where
- 12 sites in Germany, Italy
- Volunteers
- 48 people
- Sponsor
- CureVac
Prostatic Neoplasms
Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone
This study will assess different doses and regimens of radium-223 dichloride on the incidence of symptomatic skeletal events. Eligible subjects must have castration resistant prostate cancer with 2 or more skeletal metastases…
- Trial name
- NCT02023697
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Where
- 68 sites in United States, Australia and 13 more
- Volunteers
- 391 people
- Sponsor
- Bayer
Prostate Cancer
A Study of Pertuzumab in Participants With Prostate Cancer
This study will evaluate the efficacy and safety of intravenous (IV) pertuzumab in participants with hormone-refractory prostate cancer who have had no previous chemotherapy.
- Trial name
- NCT02480010
- Testing
- Pertuzumab
- Where
- 11 sites in France, Germany and 4 more
- Volunteers
- 68 people
- Sponsor
- Hoffmann-La Roche
Prostate Cancer
QLC5508 in Participants With Metastatic Prostate Cancer
This is a randomized, open-label, active-controlled, multicenter Phase III trial evaluating QLC5508 versus docetaxel in participants with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after prior…
- Trial name
- NCT07632690
- Testing
- QLC5508, Docetaxel
- Volunteers
- 700 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Prostatic Neoplasms
Docetaxel in Hormone Refractory Prostate Cancer (HRPC)[Weekly or 3weekly TAX + Prednisone in HRPC]
Primary objectives: To determine the response rate, measurable and non measurable, to Taxotere® in the second line setting. Secondary objectives: To evaluate the overall safety and toxicity of Taxotere®/prednisone combination as…
- Trial name
- NCT00268710
- Testing
- docetaxel
- Sponsor
- Sanofi
Metastatic Prostate Cancer
Phase II Sunitinib Prog Met AIPC
The purpose of this research study is to find out what effects (good and bad) Sutent has on you and your prostate cancer.
- Trial name
- NCT00599313
- Testing
- Sunitinib
- Where
- 45 sites in United States
- Volunteers
- 36 people
- Sponsor
- US Oncology Research
Benign Prostatic Hyperplasia
Urodynamic Feasibility Study Utilizing the UroLift® System
UDS evaluates the impact of Prostatic Urethral Lift (PUL) as measured by pressure flow, urodynamic testing (UDS) and an optional UroCuff Testing, an alternative urodynamic test.
- Trial name
- UDS (NCT04271020)
- Testing
- UroLift
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- NeoTract, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.